Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Verve Therapeutics, Inc.

http://www.vervetx.com

Latest From Verve Therapeutics, Inc.

Finance Watch: Lyell Raises $425m As Eight Biopharmas Go Public In One Week

Public Company Edition: Eight drug developers launched initial public offerings in the US that grossed $1.46bn combined during the week of 14 to 18 June as biotechnology stock values increased. Also, C4 Therapeutics led recent follow-on offerings, raising $180.8m. 

Financing Growth

Finance Watch: Eleven Companies Reveal $1.45bn In $100m-Plus VC Deals

Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds. 

Financing Innovation

Beam Looks Beyond Liver With Guide Therapeutics Acquisition

Research & Development BioPharmaceutical

Finance Watch: ARCH Raises $1.85bn Venture Fund To Back Early-Stage Companies

Private Company Edition: The venture capital firm said it will back biopharma, diagnostics and other opportunities in health care. In addition to the Design and TScan mega-rounds, Verve raised $94m, Vera garnered $80m and Ixaka (formerly Rexgenero) closed a £40m ($54.7m) financing. 

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Nanotechnology, Chips, etc.
    • Drug Discovery Tools
      • Genomics-Proteomics
UsernamePublicRestriction

Register